CN101006053A - 用于治疗炎症的吲哚 - Google Patents

用于治疗炎症的吲哚 Download PDF

Info

Publication number
CN101006053A
CN101006053A CNA2005800277808A CN200580027780A CN101006053A CN 101006053 A CN101006053 A CN 101006053A CN A2005800277808 A CNA2005800277808 A CN A2005800277808A CN 200580027780 A CN200580027780 A CN 200580027780A CN 101006053 A CN101006053 A CN 101006053A
Authority
CN
China
Prior art keywords
compound
represent
randomly
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800277808A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·奥洛夫森
埃德加斯·休纳
本杰明·佩尔科曼
维塔·奥佐拉
马丁斯·凯特凯维克斯
伊瓦尔斯·卡尔文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolipox AB
Original Assignee
Biolipox AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox AB filed Critical Biolipox AB
Publication of CN101006053A publication Critical patent/CN101006053A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
CNA2005800277808A 2004-06-18 2005-06-17 用于治疗炎症的吲哚 Pending CN101006053A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58040104P 2004-06-18 2004-06-18
US60/580,401 2004-06-18

Publications (1)

Publication Number Publication Date
CN101006053A true CN101006053A (zh) 2007-07-25

Family

ID=34956079

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800277808A Pending CN101006053A (zh) 2004-06-18 2005-06-17 用于治疗炎症的吲哚

Country Status (16)

Country Link
US (1) US7705023B2 (cg-RX-API-DMAC7.html)
EP (1) EP1778632B1 (cg-RX-API-DMAC7.html)
JP (1) JP2008502669A (cg-RX-API-DMAC7.html)
KR (1) KR20070028553A (cg-RX-API-DMAC7.html)
CN (1) CN101006053A (cg-RX-API-DMAC7.html)
AT (1) ATE405549T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005254782A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512252A (cg-RX-API-DMAC7.html)
CA (1) CA2570363A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005009209D1 (cg-RX-API-DMAC7.html)
ES (1) ES2315877T3 (cg-RX-API-DMAC7.html)
IL (1) IL179728A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06014535A (cg-RX-API-DMAC7.html)
RU (1) RU2007101705A (cg-RX-API-DMAC7.html)
WO (1) WO2005123673A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200610357B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108929203A (zh) * 2018-08-14 2018-12-04 重庆市化工研究院 一种芳香族乙烯基醚及其合成方法和应用
CN113233980A (zh) * 2021-04-02 2021-08-10 台州学院 一种β-氯代酸酯及α,β-不饱和酸酯类化合物的合成方法
CN118121595A (zh) * 2024-05-06 2024-06-04 广州市朝利良生物科技有限公司 化合物eh-p005j在制备促伤口愈合药物中的用途

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765775B1 (en) * 2004-06-18 2009-04-29 Biolipox AB Indoles useful in the treatment of inflammation
BRPI0512252A (pt) 2004-06-18 2008-02-19 Biolipox Ab composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
WO2006077366A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
WO2006077367A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
AR056690A1 (es) * 2005-10-14 2007-10-17 Athersys Inc Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
UA95788C2 (en) * 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
CA2652385A1 (en) 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
WO2008009924A2 (en) * 2006-07-18 2008-01-24 Biolipox Ab Indoles useful in the treatment of inflammation
MX2009011210A (es) * 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
CN102186845B (zh) 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
WO2010076566A2 (en) 2008-12-30 2010-07-08 Biolipox Ab Indoles useful in the treatment of inflammation
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ampkを活性化させるインダゾール化合物
CN114302874B (zh) * 2019-08-26 2025-02-25 国际药品株式会社 吲哚甲酰胺衍生物和包含吲哚甲酰胺衍生物的药物组合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85435A1 (fr) 1984-06-27 1986-01-24 Amylum Graanderivaten Raff Procede de preparation d'un carboxymethylamidon,carboxymethylamidon ainsi obtenu et produit de lavage contenant un tel carboxymethylamidon
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
IL84796A (en) 1986-12-17 1992-03-29 Merck Frosst Canada Inc Substituted n-benzyl-indoles and pharmaceutical compositions containing them
US5081138A (en) 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
US4960786A (en) 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
PT95899A (pt) 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
US5081145A (en) 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5374615A (en) 1990-10-31 1994-12-20 E. R. Squibb & Sons, Inc. Indole- and benzimidazole-substituted imidazole and benzimidazole derivatives
PH31175A (en) 1990-10-31 1998-03-20 Squibb & Sons Inc Indole and benzimi-dazole-substituted imidazole and benzimidazole derivatives.
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5189054A (en) 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
US5389650A (en) 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
CA2079374C (en) 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
PT633886E (pt) 1992-04-03 2001-03-30 Upjohn Co Aminas biciclicas-heterociclicas farmaceuticamente activas
US5294722A (en) 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5236916A (en) 1992-05-26 1993-08-17 E. R. Squibb & Sons, Inc. Oxadiazinone substituted indole and benzimidazole derivatives
TW229140B (cg-RX-API-DMAC7.html) 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
MX9700696A (es) 1994-07-27 1997-04-30 Sankyo Co Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
EP0800389A4 (en) 1994-12-13 1998-04-29 Smithkline Beecham Corp NEW COMPOUNDS
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
JP2000516958A (ja) 1996-08-26 2000-12-19 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
US5910622A (en) 1996-10-29 1999-06-08 Dcv, Inc. Method for treating fibrous cellulosic materials
AP9801302A0 (en) 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9716656D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
DE19742263A1 (de) 1997-09-25 1999-04-01 Asta Medica Ag Neue spezifische Immunophilin-Liganden als Antiasthmatika, Antiallergika, Antirheumatika, Immunsuppressiva, Antipsoriatika, Neuroprotektiva
BR9814340B1 (pt) 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GEP20032920B (en) 1998-02-25 2003-03-25 Genetics Inst Inhibitors of Phospholipase Enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
ID27280A (id) 1998-02-25 2001-03-22 Genetics Inst Inhibitor-inhibitor dari enzim-enzim fosfolipase
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EE200000522A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
EP1073892B1 (en) 1998-02-27 2010-11-24 Ventana Medical Systems, Inc. Automated molecular pathology apparatus having independent slide heaters
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
BR0012135A (pt) 1999-06-29 2002-07-02 Uab Research Foundation Métodos de tratamento de infecções de fungos com inibidores de enzima sintetase nad
JP2001069477A (ja) * 1999-08-31 2001-03-16 Sony Corp 番組提供システム及び番組提供方法
CA2386750A1 (en) 1999-10-22 2001-05-03 Merck & Co. Inc. Pharmaceuticals for treating obesity
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
US6353007B1 (en) 2000-07-13 2002-03-05 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents
IL154981A0 (en) 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
DE60203529T2 (de) 2001-09-27 2006-03-16 F. Hoffmann-La Roche Ag Indolderivate als cox-ii-inhibitoren
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7148250B2 (en) 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
AU2003272285A1 (en) 2002-09-06 2004-03-29 Janssen Pharmaceutica, N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
JP2007516203A (ja) 2003-07-09 2007-06-21 バイオリポックス エービー 炎症の治療に有用なインドール類
MXPA06014536A (es) 2004-06-18 2007-06-05 Biolipox Ab Indoles utiles en el tratamiento de inflamacion.
BRPI0512252A (pt) 2004-06-18 2008-02-19 Biolipox Ab composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
WO2006077364A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
US20090088472A1 (en) 2005-05-17 2009-04-02 Kouji Oohashi Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108929203A (zh) * 2018-08-14 2018-12-04 重庆市化工研究院 一种芳香族乙烯基醚及其合成方法和应用
CN113233980A (zh) * 2021-04-02 2021-08-10 台州学院 一种β-氯代酸酯及α,β-不饱和酸酯类化合物的合成方法
CN113233980B (zh) * 2021-04-02 2022-04-05 台州学院 一种β-氯代酸酯及α,β-不饱和酸酯类化合物的合成方法
CN118121595A (zh) * 2024-05-06 2024-06-04 广州市朝利良生物科技有限公司 化合物eh-p005j在制备促伤口愈合药物中的用途

Also Published As

Publication number Publication date
ZA200610357B (en) 2008-02-27
JP2008502669A (ja) 2008-01-31
RU2007101705A (ru) 2008-07-27
DE602005009209D1 (de) 2008-10-02
MXPA06014535A (es) 2007-06-05
BRPI0512252A (pt) 2008-02-19
EP1778632A1 (en) 2007-05-02
US20070287715A1 (en) 2007-12-13
AU2005254782A1 (en) 2005-12-29
WO2005123673A1 (en) 2005-12-29
CA2570363A1 (en) 2005-12-29
US7705023B2 (en) 2010-04-27
ATE405549T1 (de) 2008-09-15
IL179728A0 (en) 2007-05-15
EP1778632B1 (en) 2008-08-20
ES2315877T3 (es) 2009-04-01
KR20070028553A (ko) 2007-03-12

Similar Documents

Publication Publication Date Title
US10195186B2 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
KR20070114123A (ko) 염증 치료에 유용한 인돌
JP3267635B2 (ja) Cox−2阻害物質としてのインドール化合物
KR101751325B1 (ko) 잔틴 옥시다아제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물
KR20170135938A (ko) 브로모도메인 억제제
JP2000509719A (ja) 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用
CN110121343B (zh) 用作gpr120调节剂的双环化合物
TW200914449A (en) Organic compounds
ES2315877T3 (es) Indoles utiles en el tratamiento de inflamaciones.
CZ300570B6 (cs) Inhibitory biosyntézy prostaglandin endoperoxid H synthasy
JP7607372B2 (ja) イミダゾキノリンまたはベンゾインダゾロン化合物およびその製造中間体
JPH0853447A (ja) 新規1,3−ジヒドロ−2H−ピロロ〔2,3−b〕ピリジン−2−オンとオキサゾロ〔4,5−b〕ピリジン−2(3H)−オン化合物、その製造方法及びそれらを含む薬剤組成物
JPH05506455A (ja) ロイコトリエンd↓4拮抗剤としてのキノリニル―ベンゾヘテロ二環式誘導体
RU2407736C2 (ru) Пери-замещенные арилсульфонамидные бициклические соединения, предназначенные для лечения окклюзионного заболевания артерий
TW200902514A (en) 1-biarylazetidinone derivatives
JP2010504322A (ja) 代謝性障害の治療のための3−アミノ−ピリジン誘導体
TW200914439A (en) Novel pyrazolone-derivatives
WO2024140671A1 (zh) 一种稠三环类衍生物、包含其的药物组合物及其用途
CN101528734B (zh) 治疗代谢障碍的3-氨基吡啶衍生物
HK1217431B (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
KR20130077775A (ko) 4-티오피라졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상지질혈증의 예방 또는 치료용 약학적 조성물
HK1110580B (en) Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
TW201217336A (en) Chemical compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication